The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
Authors
Keywords
Tuberculosis, DprE1, Antituberculars, Drug target
Journal
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
Volume 97, Issue 20, Pages 8841-8848
Publisher
Springer Nature
Online
2013-09-13
DOI
10.1007/s00253-013-5218-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MDR-TB Has New Drug Foe After Fast-Track Approval
- (2013) Rebecca Voelker JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Thiolates Chemically Induce Redox Activation of BTZ043 and Related Potent Nitroaromatic Anti-Tuberculosis Agents
- (2013) Rohit Tiwari et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Advances in the development of new tuberculosis drugs and treatment regimens
- (2013) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- Identification of a small molecule with activity against drug-resistant and persistent tuberculosis
- (2013) F. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of decaprenylphosphoryl-β-D-ribose 2'-epimerase fromMycobacterium smegmatis
- (2013) Hua Li et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Approval of Novel TB Drug Celebrated--With Restraint
- (2013) J. Cohen SCIENCE
- Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening
- (2012) Sarah A. Stanley et al. ACS Chemical Biology
- Prospects for Tuberculosis Elimination
- (2012) Christopher Dye et al. Annual Review of Public Health
- In VitroCombination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis
- (2012) Benoit Lechartier et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment
- (2012) Jean Engohang-Ndong EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Exposure of Mycobacteria to Cell Wall-inhibitory Drugs Decreases Production of Arabinoglycerolipid Related to Mycolyl-arabinogalactan-peptidoglycan Metabolism
- (2012) Yoann Rombouts et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors
- (2012) S. M. Batt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis
- (2012) NICHOLAS D. WALTER et al. RESPIROLOGY
- Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis
- (2012) J. Neres et al. Science Translational Medicine
- Tuberculosis and HIV Co-Infection
- (2012) Andrzej Pawlowski et al. PLoS Pathogens
- New tuberculosis drugs on the horizon
- (2011) Stewart T Cole et al. CURRENT OPINION IN MICROBIOLOGY
- Mycobacterium tuberculosis Transmission in a Country with Low Tuberculosis Incidence: Role of Immigration and HIV Infection
- (2011) L. Fenner et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Benzothiazinones Are Suicide Inhibitors of Mycobacterial Decaprenylphosphoryl-β-d-ribofuranose 2′-Oxidase DprE1
- (2011) Claudia Trefzer et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Decaprenylphosphoryl-β-D-Ribose 2′-Epimerase, the Target of Benzothiazinones and Dinitrobenzamides, Is an Essential Enzyme in Mycobacterium smegmatis
- (2011) Paul K. Crellin et al. PLoS One
- Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis
- (2011) Ana Luisa de Jesus Lopes Ribeiro et al. PLoS One
- Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones
- (2010) M. R. Pasca et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Benzothiazinones: Prodrugs That Covalently Modify the Decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 ofMycobacterium tuberculosis
- (2010) Claudia Trefzer et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Carbon flux rerouting during Mycobacterium tuberculosis growth arrest
- (2010) Lanbo Shi et al. MOLECULAR MICROBIOLOGY
- Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance
- (2010) Giulia Manina et al. MOLECULAR MICROBIOLOGY
- Leads for antitubercular compounds from kinase inhibitor library screens
- (2010) Sophie Magnet et al. TUBERCULOSIS
- Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
- (2009) V. Makarov et al. SCIENCE
- High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
- (2009) Thierry Christophe et al. PLoS Pathogens
- Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy
- (2008) Beata A. Wolucka FEBS Journal
- Structural Analysis of the Catalytic Mechanism and Stereoselectivity inStreptomyces coelicolorAlditol Oxidase†,‡
- (2007) Federico Forneris et al. BIOCHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started